SAR vs. OBD, C4XD, HEMO, SBTX, OPTI, ONC, DEST, OBI, NSCI, and SNG
Should you be buying Sareum stock or one of its competitors? The main competitors of Sareum include Oxford BioDynamics (OBD), C4X Discovery (C4XD), Hemogenyx Pharmaceuticals (HEMO), SkinBioTherapeutics (SBTX), OptiBiotix Health (OPTI), Oncimmune (ONC), Destiny Pharma (DEST), Ondine Biomedical (OBI), NetScientific (NSCI), and Synairgen (SNG). These companies are all part of the "biotechnology" industry.
Sareum (LON:SAR) and Oxford BioDynamics (LON:OBD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends, community ranking and analyst recommendations.
Oxford BioDynamics' return on equity of -250.52% beat Sareum's return on equity.
Sareum presently has a consensus target price of GBX 304, indicating a potential upside of 628.14%. Given Sareum's higher probable upside, equities research analysts clearly believe Sareum is more favorable than Oxford BioDynamics.
36.5% of Oxford BioDynamics shares are owned by institutional investors. 4.0% of Sareum shares are owned by company insiders. Comparatively, 15.7% of Oxford BioDynamics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Sareum has higher earnings, but lower revenue than Oxford BioDynamics. Sareum is trading at a lower price-to-earnings ratio than Oxford BioDynamics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Sareum had 1 more articles in the media than Oxford BioDynamics. MarketBeat recorded 1 mentions for Sareum and 0 mentions for Oxford BioDynamics. Sareum's average media sentiment score of 0.36 beat Oxford BioDynamics' score of 0.00 indicating that Sareum is being referred to more favorably in the media.
Oxford BioDynamics received 22 more outperform votes than Sareum when rated by MarketBeat users. However, 66.13% of users gave Sareum an outperform vote while only 61.90% of users gave Oxford BioDynamics an outperform vote.
Sareum has a beta of -0.79, meaning that its share price is 179% less volatile than the S&P 500. Comparatively, Oxford BioDynamics has a beta of 0.44, meaning that its share price is 56% less volatile than the S&P 500.
Summary
Sareum and Oxford BioDynamics tied by winning 8 of the 16 factors compared between the two stocks.
Get Sareum News Delivered to You Automatically
Sign up to receive the latest news and ratings for SAR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
